Previous close | 40.90 |
Open | N/A |
Bid | 0.00 |
Ask | 0.00 |
Strike | 100.00 |
Expiry date | 2024-08-02 |
Day's range | 40.90 - 40.90 |
Contract range | N/A |
Volume | |
Open interest | N/A |
The U.S. CDC recommends that adults aged 75 years and above get an RSV shot. Those aged 60 to 74 years should only get the shot if they are at high risk for severe RSV due to chronic conditions.
Pfizer (PFE) and BioNTech's Omicron JN.1-adapted COVID-19 vaccine gets the Committee for Medicinal Products for Human Use's positive opinion recommending marketing authorization.
Moderna (MRNA) stock sinks after new data shows the efficacy of its mRNA-based RSV vaccine fell sharply in the second year and was lower than that of rival vaccines marketed by GSK and Pfizer.